$CRDF News

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Slideshow

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript

Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2

Cardiff Oncology Announces Presentation Of Phase 2 Trial Data For RAS-Mutated mCRC Treatment Onvansertib At ASCO Annual Meeting On June 2

TD Cowen Downgrades Cardiff Oncology to Hold

HC Wainwright & Co. Downgrades Cardiff Oncology to Neutral

NMS Informs Cardiff Oncology Of Agreement Termination On May 27, 2026; NMS Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship; NMS Alleges Failure By Cardiff Oncology To Use Commercially Reasonable Efforts For Onvansertib; Cardiff Oncology States NMS Termination Notice Is Ineffective And Will Continue Under Agreement

Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC

Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense

Cardiff Oncology Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $41.000K Miss $85.000K Estimate

Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology

Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026

Cardiff Oncology Appoints Mani Mohindru As President And Chief Executive Officer; Josh Muntner Appointed As CFO

Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

Cardiff Oncology To Host Key Opinion Leader Webinar To Discuss Emergent Treatment Landscape In First-Line RAS-Mutated Metastatic Colorectal Cancer On March 25

Piper Sandler Maintains Overweight on Cardiff Oncology, Lowers Price Target to $6

Cardiff Oncology Q4 EPS $(0.11) Beats $(0.20) Estimate, Sales $243.000K Beat $105.556K Estimate

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $10 Price Target

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus